Puma Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01128842
- Locations
- 🇯🇵
Investigational Site, Tokyo, Japan
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01111825
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00958724
- Locations
- 🇯🇵
Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Registration Number
- NCT00932464
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 479
- Registration Number
- NCT00915018
- Locations
- 🇫🇷
Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France
🇷🇴Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 2840
- Registration Number
- NCT00878709
- Locations
- 🇺🇸
Mercy Hospital Oncology/Hematology Center, Portland, Maine, United States
🇺🇸Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸University Hospitals, Cleveland Medical Center, Cleveland, Ohio, United States
Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00864487
Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00860223
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00838539
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00814060